心泰医疗子公司获医疗器械登记证，助力心血管介入发展
财中社12月17日电心泰医疗（02291）发布公告，宣布其子公司乐普心泰医疗科技（上海）股份有限公司的ScienCrown®经导管植入式主动脉瓣膜系统已获得中国国家药品监督管理局的医疗器械登记证。这款产品旨在解决现有TAVR手术中瓣膜扩张不良、定位不准等问题，具备多项创新设计和专利，预计将为日益增加的主动脉瓣狭窄患者提供新的治疗选择。
根据相关行业统计，2020年中国主动脉瓣狭窄患者已达440万，预计到2030年将增至520万。2023年11月30日的数据显示，我国已开展TAVR手术13572例，预计2024年全年植入量约2万例。随着心血管疾病患者数量的增加，ScienCrown®产品的上市将助力公司在心血管介入领域的进一步发展，尽管其销售表现仍受多种因素影响，包括临床推广和市场竞争。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10